AC Immune (ACIU) Stock Price, Quote, News & History | Benzinga

SPY778.570.00%QQQ751.38+0.01%BTC/USD82,634.80+0.09%DIA516.21+0.02%GLD384.50−0.02%TLT77.97−0.02%

AC Immune SA (ACIU) Stock Price, Quote, News & History

ACIUNASDAQ

Trade with Public

Trade with Public

$2.50

-0.05-1.96%

Last update: Oct 9, 4:00 PM

$2.50

-0.05-1.96%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.55

Close

$2.50

Volume / Avg.

271.33K / 202.74K

Day Range

$2.48 - $2.59

52 Wk Range

2.10 - 4.00

Market Cap

$254.43M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

7.12%

Days to Cover

25

Recent AC Immune AG News

AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response

AC Immune reported positive safety and immunogenicity results from Part 1 of its Phase 2 Parkinson's disease trial for ACI-7104.

Vandana Singh

AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline

AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.

Vandana Singh

FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks moving lower in pre-market: BBGI, MFI, JTAI, RMIX, TMCR, NMG, SHMD, ANL, CABA, FUFU.

Avi Kapoor

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

AC Immune reports Phase 2 data showing stabilized Parkinson's biomarkers, strong antibody response, and a potential slowing of disease progression in early-stage patients.

Vandana Singh

S&P 500 Moves Lower; US Crude Oil Inventories Increase

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-50.49M

Investing Cash Flow (TTM)

53.22M

Financing Cash Flow (TTM)

-373.00K

Free Cash Flow (TTM)

-51.09M

Capital Expenditure (TTM)

-594.00K

Net Change in Cash (TTM)

2.35M

Analyst Trends and Forecast

1

May

2

Aug

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$166.52M

PE Ratio (TTM)

-

PE Ratio (FWD)

14.90

PEG Ratio (TTM)

-

PS Ratio (TTM)

12.23

PB Ratio (TTM)

5.97

Earnings Yield % (TTM)

-20.37%

Earnings Yield % (FWD)

6.71%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.42

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$958.00K

Total Cash

$27.76M

Debt to Equity

0.12

Issuance of Debt (TTM)

-$958.00K

Repayment of Debt (TTM)

-$958.00K